These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17690487

  • 41. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 42. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 43. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 44. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J, Booth NA, Declerck PJ, Gils A.
    J Thromb Haemost; 2008 Nov; 6(11):1884-91. PubMed ID: 18752580
    [Abstract] [Full Text] [Related]

  • 45. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T, Gando S, Mizugaki A, Yanagida Y, Jesmin S, Yokota H, Ieko M.
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [Abstract] [Full Text] [Related]

  • 46. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T.
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
    [Abstract] [Full Text] [Related]

  • 47. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 48. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Nov; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 49. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 50. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
    Denorme F, Wyseure T, Peeters M, Vandeputte N, Gils A, Deckmyn H, Vanhoorelbeke K, Declerck PJ, De Meyer SF.
    Stroke; 2016 Sep; 47(9):2419-22. PubMed ID: 27470988
    [Abstract] [Full Text] [Related]

  • 51. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 52. Fibrinolytic Changes in Women with Preeclampsia.
    Godtfredsen AC, Sidelmann JJ, Dolleris BB, Jørgensen JS, Johansen EKJ, Pedersen MFB, Palarasah Y, Gram JB.
    Clin Appl Thromb Hemost; 2022 May 01; 28():10760296221126172. PubMed ID: 36217728
    [Abstract] [Full Text] [Related]

  • 53. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
    Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabín J.
    Stroke; 2004 Sep 01; 35(9):2123-7. PubMed ID: 15243150
    [Abstract] [Full Text] [Related]

  • 54. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr 01; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 55. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
    Chhikara A, Sharma S, Chandra J, Nangia A.
    Indian J Pediatr; 2017 Jan 01; 84(1):25-30. PubMed ID: 27487812
    [Abstract] [Full Text] [Related]

  • 56. A challenging issue in COVID-19 infection: The relationship between PA1-1 and TAFI levels in patients with coagulation disorder: A retrospective and observational study.
    Altin N, Tiğlioğlu P, Ulusoy TU, Aydin FN, Kar İ, Karakoc B, Utebey G.
    Medicine (Baltimore); 2024 Apr 12; 103(15):e37802. PubMed ID: 38608056
    [Abstract] [Full Text] [Related]

  • 57. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF.
    Curr Med Chem; 2004 Sep 12; 11(17):2335-48. PubMed ID: 15379716
    [Abstract] [Full Text] [Related]

  • 58. Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.
    Mazur P, Myć J, Natorska J, Plens K, Plicner D, Grudzień G, Kapelak B, Undas A.
    J Thromb Thrombolysis; 2018 Aug 12; 46(2):193-202. PubMed ID: 29855781
    [Abstract] [Full Text] [Related]

  • 59. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Aug 12; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 60. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May 12; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.